Nabaltec AG

  • WKN: A0KPPR
  • ISIN: DE000A0KPPR7
  • Land: Deutschland

Nachricht vom 22.07.2021 | 10:44

Nabaltec AG: Dr. Alexander Risch takes over as new COO, succeeding Dr. Michael Klimes

DGAP-News: Nabaltec AG / Key word(s): Personnel
22.07.2021 / 10:44
The issuer is solely responsible for the content of this announcement.

Nabaltec AG: Dr. Alexander Risch takes over as new COO, succeeding Dr. Michael Klimes

Schwandorf, 22 July 2021 - Nabaltec AG is announcing a change in its Management Board, as the Supervisory Board is going to appoint Dr. Alexander Risch to a 4-year term on the Management Board effective 1 October 2021. Dr. Michael Klimes, who has been serving on Nabaltec AG's three-member Management Board as COO since 2017, has chosen not to extend his contract, which expires on 31 December 2021.

"In Dr. Alexander Risch, we have been able to secure an experienced mineralogist who will help us continue to generate growth from Nabaltec's innovative solutions," reported Johannes Heckmann, CEO of Nabaltec AG. "We are looking forward to working together in the future and his additional input."

Dr. Alexander Risch completed his studies in mineralogy at the Friedrich-Alexander-University of Erlangen-Nuremberg and has worked at the Institute of Geosciences in Erlangen on a project of Germany's Federal Ministry of Education and Research focusing on high-temperature oxide ceramic superconductors, in the course of which he successfully completed his doctorate. Dr. Alexander Risch began working at Hoffmann Mineral GmbH in 1999. From 2006 through 2021, he headed that company's global sales, marketing and order processing operations, during which time he gained extensive experience with industrial fillers and their functions. As of 1 January 2022, Dr. Alexander Risch as COO will have sole responsibility for the company's departments research and development, as well as for production and sales. Until that date, Nabaltec's Management Board will operate as a four-member body for a transitional period. The employment agreements of the Management Board members Johannes Heckmann (Chairman of the Management Board and CEO) and Günther Spitzer (CFO) have each been extended by five years.

Gerhard Witzany, Chairman of the Supervisory Board, stated as follows: "The Supervisory Board accepted Dr. Klimes' decision with great regret. Dr. Michael Klimes successfully performed his tasks with expertise and commitment, and we would like to thank him expressly for his consistently excellent work and for our trust-based relationship."


About Nabaltec AG:
Nabaltec AG, with registered office in Schwandorf, a chemicals business which has received multiple awards for innovativeness, manufactures, develops and distributes highly specialized products based on aluminum hydroxide and aluminum oxide on an industrial scale through its two product segments, "Functional Fillers" and "Specialty Alumina." The company's product range includes eco-friendly flame retardant fillers and functional additives for the plastics industry. Flame retardant fillers are used e.g. in cables in tunnels, airports, high-rise buildings and electronic devices, while additives have applications in catalysis and in electric vehicles. Nabaltec also produces specialty oxides for use in technical ceramics, the refractory and polishing industries. Nabaltec maintains production sites in Germany and the US and plans to continue to develop its market position by expanding capacity, further optimizing processes and quality and making strategic extensions to its product range. On the strength of its specialty products, the company strives to attain the market leadership in each segment.

Contact:

Heidi Wiendl-Schneller Frank Ostermair/Vera Müller
Nabaltec AG Better Orange IR & HV AG
Phone: +49 9431 53-202 Phone: +49 89 8896906-14
Fax: +49 9431 53-260 Fax: +49 89 8896906-66
E-mail: InvestorRelations@nabaltec.de E-mail: nabaltec@better-orange.de


22.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021